Verteporfin
Based on 286 publication(s) in Google Scholar
Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis. Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.15%
- CAS 番号: 129497-78-5
- 分子式: C41H42N4O8
- 分子量:718.79
-
保管条件:
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
MedChemExpress(MCE)の使用を引用している文献 Verteporfin
More- Cancer Cell. 2019 Sep 16;36(3):302-318.e7. [Abstract]
- Nat Mater. 2025 Nov 5. [Abstract]
- Cell Res. 2022 Jun;32(6):543-554. [Abstract]
- Cell Res. 2020 Mar;30(3):229-243. [Abstract]
- Cancer Discov. 2025 Jan 13;15(1):202-226. [Abstract]
- Nat Biomed Eng. 2025 Jul;9(7):1039-1061. [Abstract]
- Nat Aging. 2026 Jan 2. [Abstract]
- Bioact Mater. 2022 Feb 1:14:402-415. [Abstract]
- Bioact Mater. 2021 Jun 1:7:364-376. [Abstract]
- Cell Host Microbe. 2026 Feb 11;34(2):245-262.e8. [Abstract]
- Cancer Res. 2025 Dec 31. [Abstract]
- Cancer Res. 2025 Jan 15;85(2):263-276. [Abstract]
- Cancer Res. 2023 Apr 4;83(7):1016-1030. [Abstract]
- Sci Bull. 2021 May 15;66(9):925-936. [Abstract]
- Nat Neurosci. 2022 Jul;25(7):849-864. [Abstract]
- Bone Res. 2024 Aug 21;12(1):45. [Abstract]
- Adv Funct Mater. 2025 Jun 29.
- Nat Commun. 2025 Sep 25;16(1):8409. [Abstract]
- Nat Commun. 2024 Dec 3;15(1):10378. [Abstract]
- Nat Commun. 2024 Aug 13;15(1):6953. [Abstract]
- Nat Commun. 2022 Oct 5;13(1):5871. [Abstract]
- Hepatology. 2021 Oct;74(4):2133-2153. [Abstract]
- Hepatology. 2020 May;71(5):1643-1659. [Abstract]
- ACS Nano. 2024 Aug 13;18(32):21009-21023. [Abstract]
- ACS Nano. 2020 Nov 24;14(11):14907-14918. [Abstract]
- J Adv Res. 2025 Nov 19:S2090-1232(25)00929-4. [Abstract]
- Redox Biol. 2025 May:82:103597. [Abstract]
- Redox Biol. 2020 Oct;37:101745. [Abstract]
- Mol Cell. 2019 Jan 3;73(1):7-21.e7. [Abstract]
- Matter. 2022 Dec.
- Gut Microbes. 2024 Jan-Dec;16(1):2333790. [Abstract]
- J Nanobiotechnology. 2024 Aug 20;22(1):495. [Abstract]
- Theranostics. 2021 Mar 5;11(11):5197-5213. [Abstract]
- Genes Dis. 2023 Sep 16;11(4):101114. [Abstract]
- Genes Dis. 2021 Nov 19;9(6):1701-1715. [Abstract]
- J Exp Clin Cancer Res. 2023 Jul 18;42(1):172. [Abstract]
- J Exp Clin Cancer Res. 2022 Dec 29;41(1):364. [Abstract]
- J Exp Clin Cancer Res. 2022 Jun 3;41(1):193. [Abstract]
- J Exp Clin Cancer Res. 2020 Jan 28;39(1):22. [Abstract]
- Adv Sci (Weinh). 2026 May 26:e15158. [Abstract]
- Adv Sci (Weinh). 2025 May 20:e2416489. [Abstract]
- Adv Sci (Weinh). 2025 May;12(17):e2410909. [Abstract]
- Adv Sci (Weinh). 2024 Apr;11(16):e2308531. [Abstract]
- MedComm. 2023 Jun 5;4(3):e293. [Abstract]
- Adv Sci (Weinh). 2022 May;9(13):e2104682. [Abstract]
- Sci Adv. 2020 May 22;6(21):eaaz5913. [Abstract]
- Cell Death Differ. 2023 Jul;30(7):1648-1665. [Abstract]
- Biomaterials. 2022 Apr:283:121466. [Abstract]
- Neuro Oncol. 2022 Dec 1;24(12):2107-2120. [Abstract]
- Mol Biomed. 2026 Apr 17;7(1):53. [Abstract]
- Cell Death Dis. 2026 Apr 23;17(1):539. [Abstract]
- Cell Death Dis. 2026 Mar 26;17(1):381. [Abstract]
- Cell Death Dis. 2026 Jan 21;17(1):98. [Abstract]
- Cell Death Dis. 2026 Jan 9;17(1):20. [Abstract]
- Cell Death Dis. 2025 Jun 5;16(1):438. [Abstract]
- Cell Death Dis. 2025 May 28;16(1):422. [Abstract]
- Cell Death Dis. 2025 Mar 19;16(1):186. [Abstract]
- Cell Death Dis. 2025 Feb 3;16(1):64. [Abstract]
- Cell Death Dis. 2025 Jan 14;16(1):17. [Abstract]
- Cell Death Dis. 2022 Oct 1;13(10):839. [Abstract]
- Cell Death Dis. 2022 Sep 10;13(9):783. [Abstract]
- Cell Death Dis. 2020 Oct 31;11(10):938. [Abstract]
- Small. 2025 Apr 3:e2501491. [Abstract]
- Small. 2025 Jan 23:e2410214. [Abstract]
- Cancer Lett. 2024 Apr 10:587:216703. [Abstract]
- Cancer Lett. 2022 Aug 10:541:215749. [Abstract]
- Small. 2022 Mar;18(12):e2106568. [Abstract]
- Small. 2020 May 17;e2001837. [Abstract]
- Cell Commun Signal. 2024 May 16;22(1):277. [Abstract]
- Cell Commun Signal. 2023 Oct 30;21(1):308. [Abstract]
- Cell Commun Signal. 2022 Apr 12;20(1):52. [Abstract]
- Phytomedicine. 2026 Jun:155:158086. [Abstract]
- Phytomedicine. 2025 May 17:143:156865. [Abstract]
- Phytomedicine. 2025 May 21:143:156879. [Abstract]
- Phytomedicine. 2024 Dec:135:156095. [Abstract]
- Phytomedicine. 2024 Dec:135:155572. [Abstract]
- Phytomedicine. 2022 Dec:107:154466. [Abstract]
- Phytomedicine. 2022 Feb:96:153913. [Abstract]
- Phytomedicine. 2020 Nov:78:153294. [Abstract]
- Mater Today Bio. 2025 Apr 10:32:101757. [Abstract]
- Mater Today Bio. 2024 May 27:26:101104. [Abstract]
- Adv Healthc Mater. 2022 Nov;11(21):e2201032. [Abstract]
- Acta Biomater. 2026 Jun:216:287-297. [Abstract]
- Acta Biomater. 2026 May 14:S1742-7061(26)00314-4. [Abstract]
- Acta Pharmacol Sin. 2025 Nov 1. [Abstract]
- Acta Biomater. 2025 Jan 15:192:77-89. [Abstract]
- Acta Pharmacol Sin. 2025 May;46(5):1345-1360. [Abstract]
- Acta Pharmacol Sin. 2024 Dec;45(12):2657-2671. [Abstract]
- Cell Death Discov. 2023 Oct 20;9(1):385. [Abstract]
- Cell Death Discov. 2023 Sep 9;9(1):339. [Abstract]
- Cell Death Discov. 2023 Jan 25;9(1):30. [Abstract]
- Cell Death Discov. 2022 Mar 12;8(1):111. [Abstract]
- Collagen Leather. 2026 Apr 2;8(1):11.
- J Orthop Translat. 2025 Jul 12:54:8-25. [Abstract]
- J Transl Med. 2023 Apr 1;21(1):238. [Abstract]
- Proc Natl Acad Sci U S A. 2024 Sep 24;121(39):e2403062121. [Abstract]
- Dev Cell. 2025 Jun 25:S1534-5807(25)00362-4. [Abstract]
- Oncogene. 2022 Feb;41(7):930-942. [Abstract]
- Apoptosis. 2024 Dec;29(11-12):2161-2182. [Abstract]
- Int J Nanomedicine. 2024 Mar 13:19:2611-2623. [Abstract]
- Int J Nanomedicine. 2023 Nov 1:18:6185-6198. [Abstract]
- Neural Regen Res. 2025 Mar 1;20(3):887-899. [Abstract]
- Mol Med. 2025 Mar 8;31(1):90. [Abstract]
- Cell Mol Gastroenterol Hepatol. 2025 Sep 22:101640. [Abstract]
- Biofabrication. 2024 Sep 2;16(4). [Abstract]
- Antioxidants (Basel). 2023 Apr 24;12(5):990. [Abstract]
- Free Radic Biol Med. 2026 Aug 16:252:55-68. [Abstract]
- Free Radic Biol Med. 2026 Mar 25:250:174-188. [Abstract]
- Free Radic Biol Med. 2025 May:232:330-339. [Abstract]
- J Anim Sci Biotechnol. 2026 Mar 17;17(1):50. [Abstract]
- EMBO Mol Med. 2025 Dec 1. [Abstract]
- Clin Transl Med. 2024 Mar;14(3):e1630. [Abstract]
- J Genet Genomics. 2022 Dec;49(12):1101-1113. [Abstract]
- Clin Transl Med. 2021 Sep;11(9):e478. [Abstract]
- EMBO Mol Med. 2018 Nov;10(11). pii: e8699. [Abstract]
- ACS Appl Mater Interfaces. 2025 Jul 2;17(26):37601-37616. [Abstract]
- Stem Cell Res Ther. 2021 Oct 7;12(1):523. [Abstract]
- Cell Rep. 2026 Mar 30;45(4):117200. [Abstract]
- Cell Prolif. 2025 Jul 4:e70085. [Abstract]
- Cell Prolif. 2024 Aug;57(8):e13640. [Abstract]
- Cell Prolif. 2022 May;55(5):e13221. [Abstract]
- Br J Pharmacol. 2024 Oct 2. [Abstract]
- Cell Syst. 2018 Apr 25;6(4):424-443.e7. [Abstract]
- Sci Signal. 2025 Oct 21;18(909):eadx2532. [Abstract]
- Cancer Cell Int. 2022 Mar 9;22(1):113. [Abstract]
- NPJ Regen Med. 2021 Mar 26;6(1):16. [Abstract]
- Cancer Cell Int. 2021 Feb 19;21(1):128. [Abstract]
- Cancer Cell Int. 2019 Jul 12:19:179. [Abstract]
- Redox Rep. 2026 Dec;31(1):2643967. [Abstract]
- Mol Cancer Ther. 2025 Apr 28:OF1-OF13. [Abstract]
- Neurosci Bull. 2026 Mar 22. [Abstract]
- JCI Insight. 2024 Dec 20;9(24):e178535. [Abstract]
- Biomater Adv. 2026 Aug:185:214849. [Abstract]
- Biomater Adv. 2023 Jun:149:213413. [Abstract]
- J Dent Res. 2019 Jul;98(8):920-929. [Abstract]
- Biochem Pharmacol. 2026 Jun:248:117837. [Abstract]
- Cell Biosci. 2025 Dec 23;16(1):7. [Abstract]
- Biochem Pharmacol. 2026 Feb:244:117602. [Abstract]
- Biochem Pharmacol. 2026 Jan;243(Pt 2):117543. [Abstract]
- Biochem Pharmacol. 2025 Jul 19:241:117185. [Abstract]
- Biochem Pharmacol. 2024 Feb:220:116009. [Abstract]
- Cell Mol Life Sci. 2023 Jun 21;80(7):186. [Abstract]
- J Bone Miner Res. 2021 Aug;36(8):1521-1534. [Abstract]
- Mol Ther Nucleic Acids. 2021 Feb 26:24:241-252. [Abstract]
- Cell Biosci. 2020 Dec 22;10(1):146. [Abstract]
- Int Endod J. 2026 Jun 2. [Abstract]
- Life Sci. 2026 Mar 1:388:124195. [Abstract]
- Life Sci. 2023 Jun 1:322:121671. [Abstract]
- Food Funct. 2025 Jun 16;16(12):4822-4836. [Abstract]
- J Cell Biol. 2025 Dec 1;224(12):e202501122. [Abstract]
- Transl Res. 2023 May:255:85-96. [Abstract]
- Acs Biomater Sci Eng. 2022 Feb 14;8(2):598-609. [Abstract]
- Cells. 2022 Jan 11;11(2):237. [Abstract]
- Cells. 2020 Apr 18;9(4):1010. [Abstract]
- Colloids Surf B Biointerfaces. 2025 Jul 17:255:114963. [Abstract]
- Cancer Immunol Immunother. 2025 Nov 3;74(12):356. [Abstract]
- Eur J Pharmacol. 2026 Apr 15:1021:178827. [Abstract]
- Respir Res. 2025 Feb 12;26(1):51. [Abstract]
- Pharmaceuticals (Basel). 2023 Oct 12;16(10):1444. [Abstract]
- Biomolecules. 2026 Mar 13;16(3):429. [Abstract]
- Int J Mol Sci. 2026 Jan 20;27(2):1020. [Abstract]
- ACS Appl Bio Mater. 2025 Oct 25. [Abstract]
- Int J Mol Sci. 2025 Sep 18;26(18):9129. [Abstract]
- Int Immunopharmacol. 2024 Mar 30:130:111766. [Abstract]
- Int Immunopharmacol. 2023 Jun:119:110220. [Abstract]
- Int Immunopharmacol. 2020 Mar 6;82:106366. [Abstract]
- Neurochem Int. 2023 Oct:169:105586. [Abstract]
- J Periodontal Res. 2026 Jan 24. [Abstract]
- Colloids Surf A Physicochem Eng Asp. 2025 Dec 27.
- BMC Biol. 2024 Nov 15;22(1):262. [Abstract]
- J Pathol. 2021 Sep;255(1):95-106. [Abstract]
- J Ovarian Res. 2024 Mar 15;17(1):62. [Abstract]
- Front Cell Dev Biol. 2021 May 12:9:639111. [Abstract]
- Int Dent J. 2026 Jun 27;76(5):109698. [Abstract]
- Chem Biol Interact. 2024 Dec 31:111368. [Abstract]
- Biofactors. 2024 Nov-Dec;50(6):1113-1133. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2024 Mar;1870(3):167012. [Abstract]
- Mol Med Rep. 2020 Nov;22(5):3955-3961. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2020 Mar 1;1866(3):165625. [Abstract]
- Cancer Sci. 2026 Jul;117(7):1883-1893. [Abstract]
- Cancer Sci. 2026 Mar;117(3):695-710. [Abstract]
- Sci Rep. 2025 Nov 24;15(1):41644. [Abstract]
- Sci Rep. 2025 Oct 6;15(1):34796. [Abstract]
- Sci Rep. 2025 Jul 13;15(1):25338. [Abstract]
- Am J Pathol. 2023 Sep;193(9):1208-1222. [Abstract]
- Mediators Inflamm. 2021 Jul 28:2021:9954909. [Abstract]
- Ultrasonics. 2023 May:131:106949. [Abstract]
- Cancers (Basel). 2023 Jan 31;15(3):886. [Abstract]
- Mol Cell Biochem. 2026 Jun;481(6):2449-2466. [Abstract]
- J Cell Mol Med. 2026 Jun;30(11):e71224. [Abstract]
- Cell Signal. 2026 Jul:143:112459. [Abstract]
- Virol Sin. 2025 Aug;40(4):658-668. [Abstract]
- Cell Signal. 2024 Jul:119:111186. [Abstract]
- Oncol Rep. 2021 Oct;46(4):224. [Abstract]
- Oncol Rep. 2021 Jan;45(1):83-94. [Abstract]
- J Cell Mol Med. 2020 Jul;24(14):8179-8193. [Abstract]
- iScience. 2026 Jun 5;29(6):116268. [Abstract]
- Neurochem Res. 2025 Dec 29;51(1):24. [Abstract]
- iScience. 2025 Jan 21;28(2):111854. [Abstract]
- Acta Biochim Biophys Sin (Shanghai). 2024 Apr 25;56(4):621-633. [Abstract]
- Front Cell Neurosci. 2018 Dec 11:12:489. [Abstract]
- Biochim Biophys Acta Mol Cell Res. 2026 Mar;1873(3):120111. [Abstract]
- FASEB J. 2025 Aug 31;39(16):e70936. [Abstract]
- FASEB J. 2025 Feb 28;39(4):e70410. [Abstract]
- FASEB J. 2023 Feb;37(2):e22783. [Abstract]
- J Biol Chem. 2024 Jul 1:107512. [Abstract]
- J Biol Chem. 2024 Apr;300(4):107208. [Abstract]
- J Biol Chem. 2022 Apr;298(4):101792. [Abstract]
- Development. 2025 Jun 16:dev.204483. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 10. [Abstract]
- J Biomed Mater Res A. 2023 Nov;111(11):1781-1797. [Abstract]
- J Anim Sci. 2023 Jan 3:101:skad312. [Abstract]
- Mol Immunol. 2019 Mar:107:29-40. [Abstract]
- ACS Chem Biol. 2025 Feb 21;20(2):464-478. [Abstract]
- Dis Model Mech. 2024 Oct 1;17(10):dmm050900. [Abstract]
- Anim Cells Syst. 2022 Nov 7;26(6):300-309. [Abstract]
- Arch Med Res. 2020 Feb;51(2):124-134. [Abstract]
- Cell Mol Bioeng. 2026 May 15.
- Exp Cell Res. 2025 Feb 21;446(1):114461. [Abstract]
- Exp Cell Res. 2024 Mar 1;436(1):113956. [Abstract]
- Arch Biochem Biophys. 2023 Jul 15:743:109642. [Abstract]
- Exp Cell Res. 2020 Feb 1;387(1):111745. [Abstract]
- Mol Cell Endocrinol. 2024 Aug 1:589:112248. [Abstract]
- J Pharm Biomed Anal. 2022 Jan 20:208:114473. [Abstract]
- Exp Dermatol. 2022 Mar;31(3):320-329. [Abstract]
- BMC Gastroenterol. 2025 May 8;25(1):342. [Abstract]
- Mol Cell Probes. 2024 Jul 5:76:101968. [Abstract]
- Mol Biotechnol. 2024 Sep;66(9):2558-2568. [Abstract]
- Tissue Cell. 2025 Aug 28:98:103111. [Abstract]
- J Steroid Biochem Mol Biol. 2025 Jun 2:252:106799. [Abstract]
- Exp Eye Res. 2024 Jan:238:109747. [Abstract]
- Oral Dis. 2024 May;30(4):2425-2438. [Abstract]
- Am J Cancer Res. 2020 Jan 1;10(1):196-210. [Abstract]
- J Cell Biochem. 2020 Mar;121(3):2343-2353. [Abstract]
- Acta Histochem. 2026 Apr 27;128(3):152335. [Abstract]
- Theriogenology. 2026 Apr 1:254:117813. [Abstract]
- PLoS One. 2026 Feb 13;21(2):e0342649. [Abstract]
- J Pharmacol Sci. 2025 Apr;157(4):219-228. [Abstract]
- PLoS One. 2024 Aug 9;19(8):e0308619. [Abstract]
- Reprod Sci. 2023 Sep;30(9):2715-2727. [Abstract]
- Cancer Manag Res. 2021 Jun 17:13:4829-4840. [Abstract]
- Biochem Biophys Res Commun. 2022 Dec 25;636(Pt 1):197-204. [Abstract]
- Biochem Biophys Res Commun. 2020 Jun 30;527(3):624-630. [Abstract]
- Biochem Biophys Res Commun. 2019 May 14;512(4):736-741. [Abstract]
- Biochem Biophys Res Commun. 2019 Mar 5;510(2):219-223. [Abstract]
- J Oral Pathol Med. 2020 Apr;49(4):305-310. [Abstract]
- Arch Oral Biol. 2019 Apr:100:23-32. [Abstract]
- Oncol Lett. 2021 Oct;22(4):724. [Abstract]
- Eur J Oral Sci. 2025 Jan 8:e13034. [Abstract]
- Curr Med Sci. 2024 Aug;44(4):718-725. [Abstract]
- Connect Tissue Res. 2022 Sep;63(5):498-513. [Abstract]
- Stem Cells Dev. 2020 Oct 15;29(20):1309-1319. [Abstract]
- Tohoku J Exp Med. 2026 Apr 23. [Abstract]
- Res Sq. 2026 Mar 11.
- SSRN. 2026 Jan 14.
- University of Otago. 2025 Oct 7.
- bioRxiv. 2025 July 15.
- Res Sq. 2025 May 29.
- bioRxiv. 2025 April 14.
- Heliyon. 2024 Sep 2;10(17):e37265. [Abstract]
- bioRxiv. 2024 Dec 5:2024.12.04.626665. [Abstract]
- bioRxiv. 2024 August 28.
- Biomed Pharmacother. 2024 Jul 31:178:117220. [Abstract]
- Research Square Preprint. 2024 May 2.
- Biomed Pharmacother. 2024 May 24:176:116768. [Abstract]
- Research Square Preprint. 2024 May 14.
- Research Square Preprint. 2024 Mar 19.
- Heliyon. 2024 Jan 16;10(2):e24602. [Abstract]
- SSRN. 2023 Nov 29.
- Research Square Preprint. 2023 Sep 26.
- Research Square Preprint. 2023 Jun 13.
- Research Square Print. 2023 Mar 16.
- Biomed Pharmacother. 2023 Mar:159:114302. [Abstract]
- Research Square Print. November 17th, 2022
- Research Square Print. September 30th, 2022.
- Research Square Print. October 27th, 2022.
- Research Square Print. 2022 Aug.
- Research Square Print. 2022 Aug.
- Oxid Med Cell Longev. 2022 Jul 20:2022:9684062. [Abstract]
- Research Square Print. 2022 Jun.
- Research Square Preprint. 2022 May.
- Elife. 2022 Mar 14;11:e75449. [Abstract]
- Research Square Preprint. 2022 Jan.
- Research Square Preprint. 2021 Sep.
- Biomed Pharmacother. 2020 Jun;126:110080. [Abstract]
- bioRxiv. 2020 May.
-
WB
-
IF
-
Cell Proliferation/Viability Assay
-
WB
-
IHC
YAP アイソフォーム固有の製品をすべて表示
More
生物活性
|
YAP/TAZ-TEAD |
Verteporfin is specifically selected by PDX-cell screening. The concentrations to cause 50% growth inhibition (GI50) for PhLO, PhLH, and PhLK are 228 nM, 395 nM, and 538 nM, respectively, whereas GI50 for ALL-1, TCC-Y/sr, and NPhA1 are 3.93 μM, 2.11 μM, and 5.61 μM, respectively. GSH significantly reduces the sensitivity of 2 out of 3 PDX cells to verteporfin. Verteporfin reduces the mitochondrial membrane potential in PDX cells[1]. Verteporfin reduces the PTX-resistance on HCT-8/T cells by inhibiting YAP expression and combination therapy with verteporfin and NSC 125973 shows synergism on inhibition of YAP and cytotoxicity to HCT-8/T[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 129497-78-5
-
性状 Solid
-
分子量 718.79
-
分子式 C41H42N4O8
-
Color Brown to black
-
SMILES
C[C@]1(/C2=C/C(N3)=C4C)C(C(/C=C(C(C)=C/5C=C)\NC5=C/C6=N/C(C(CCC(OC)=O)=C6C)=C\C3=C4CCC(O)=O)=N2)=CC=C(C(OC)=O)[C@H]1C(OC)=O.C[C@]7(/C8=C/C(N9)=C%10C)C(C(/C=C(C(C)=C/%11C=C)\NC%11=C/C%12=N/C(C(CCC(O)=O)=C%12C)=C\C9=C%10CCC(OC)=O)=N8)=CC=C(C(OC)=O)[C@H]7C(OC)=O
-
別名
ベルテポルフィン; CL 318952
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications (286)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse. [Abstract]2019 Sep 16;36(3):302-318.e7. PMID: 31474569
Verteporfin purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2019 Sep 16;36(3):302-318.e7. [Abstract]
Combined treatment of GFAP-Ptch tumor cells with Verteporfin (VP; 24 hours) and CD532 additively decreases proliferation of ZIC1+ tumor cells relative to individual treatments.
-
Nat Mater
2025 Nov 5. PMID: 41193876 -
Cell Res
Meningeal lymphatics regulate radiotherapy efficacy through modulating anti-tumor immunity. [Abstract]2022 Jun;32(6):543-554. PMID: 35301438
Verteporfin purchased from MedChemExpress. Usage Cited in: Cell Res. 2022 Jun;32(6):543-554. [Abstract]
Survival of mice with striatal GL261 tumor injection with or without RT, saline plus laser treatment, or Verteporfin (Visudyne; 2 mg/mL; 5 μL was injected into the cisterna magna; 15 min) plus laser treatment.
-
Cell Res
2020 Mar;30(3):229-243. PMID: 32094452
Verteporfin purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Mar;30(3):229-243. [Abstract]
The representative images of dCLNs and sCLNs 2 weeks after striatal injection of GL261 or B16 cells into mice treated with Vehicle + Laser or =Verteporfin (Visudyne; 2 mg/mL; 5 μL was injected into the cisterna magna; 15 min) + Laser.
-
Cancer Discov
Neuro-mesenchymal interaction mediated by a β2 adrenergic-nerve growth factor feedforward loop promotes colorectal cancer progression. [Abstract]2025 Jan 13;15(1):202-226. PMID: 39137067
Verteporfin purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2025 Jan 13;15(1):202-226. [Abstract]
Verteporfin (0.5 μM; pretreatment for 4 hours followed by 30-minute treatment) inhibits norepinephrine (NE)- or dexmedetomidine (DEX)-induced YAP dephosphorylation (activated state) in AKP tumor cells, restores phosphorylation levels of LATS1 and YAP, and blocks ADRA2A/Gi-mediated YAP signaling pathway activation.
-
Nat Biomed Eng
Spatially resolved subcellular protein-protein interactomics in drug-perturbed lung-cancer cultures and tissues. [Abstract]2025 Jul;9(7):1039-1061. PMID: 39478233 -
Nat Aging
2026 Jan 2. PMID: 41482519 -
Bioact Mater
Verteporfin-mediated on/off photoswitching functions synergistically to treat choroidal vascular diseases. [Abstract]2022 Feb 1:14:402-415. PMID: 35386820 -
Bioact Mater
2021 Jun 1:7:364-376. PMID: 34466738 -
Cell Host Microbe
Enterococcus faecalis-derived lactic acid suppresses macrophage activation to facilitate persistent and polymicrobial wound infections. [Abstract]2026 Feb 11;34(2):245-262.e8. PMID: 41605216 -
Cancer Res
2025 Dec 31. PMID: 41474982 -
Cancer Res
Ephrin A1 Stimulates CCL2 Secretion to Facilitate Premetastatic Niche Formation and Promote Gastric Cancer Liver Metastasis. [Abstract]2025 Jan 15;85(2):263-276. PMID: 39412948 -
Cancer Res
WNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor Growth. [Abstract]2023 Apr 4;83(7):1016-1030. PMID: 36622276 -
Sci Bull
Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2. [Abstract]2021 May 15;66(9):925-936. PMID: 33318880
Verteporfin purchased from MedChemExpress. Usage Cited in: Sci Bull. 2021 May 15;66(9):925-936. [Abstract]
Verteporfin displays a complete suppression of viral CPE at 0.31 µM. Viral N protein expression in infected Vero E6 cells was assessed by immunofluorescence.
Verteporfin purchased from MedChemExpress. Usage Cited in: Sci Bull. 2021 May 15;66(9):925-936. [Abstract]
Protoporphyrin IX and Verteporfin effectively prevent SARS-CoV-2 infection in the mouse model expressing human ACE2. Much fewer cells expressed viral N protein in the Protoporphyrin IX and Verteporfin (20 µM) groups compared to the DMSO group.
Verteporfin purchased from MedChemExpress. Usage Cited in: Sci Bull. 2021 May 15;66(9):925-936. [Abstract]
Verteporfin (0.31 µM) inhibits N protein expression in SARS-CoV-2-infected Vero E6 cells.
Verteporfin purchased from MedChemExpress. Usage Cited in: Sci Bull. 2021 May 15;66(9):925-936. [Abstract]
Antiviral effect and cell cytotoxicity of protoporphyrin IX and verteporfin. The viral RNA production in the supernatant of infected Vero E6 cells was quantified with qRT-PCR. The value at each compound concentration was presented relative to that at zero compound concentration that was set as 100% (blue).
-
Nat Neurosci
The embryonic zebrafish brain is seeded by a lymphatic-dependent population of mrc1+ microglia precursors. [Abstract]2022 Jul;25(7):849-864. PMID: 35710983
Verteporfin purchased from MedChemExpress. Usage Cited in: Nat Neurosci. 2022 Jul;25(7):849-864. [Abstract]
Verteporfin (1 µM)-treated animals exposed to 640 nm in the head exhibits less mrc1a+ cells in the brain compared to non-photoactivated control animals.
-
Bone Res
Rejuvenation of BMSCs senescence by pharmacological enhancement of TFEB-mediated autophagy alleviates aged-related bone loss and extends lifespan in middle aged mice. [Abstract]2024 Aug 21;12(1):45. PMID: 39164234 -
-
Nat Commun
Macrophage-derived amphiregulin induces myofibroblast transition in adipogenic lineage precursors near Staphylococcus aureus abscess in bone marrow. [Abstract]2025 Sep 25;16(1):8409. PMID: 40998791 -
Nat Commun
2024 Dec 3;15(1):10378. PMID: 39627202 -
Nat Commun
2024 Aug 13;15(1):6953. PMID: 39138205 -
Nat Commun
BNC1 deficiency-triggered ferroptosis through the NF2-YAP pathway induces primary ovarian insufficiency. [Abstract]2022 Oct 5;13(1):5871. PMID: 36198708
Verteporfin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Oct 5;13(1):5871. [Abstract]
Mice are injected with either Verteporfin (VP; 100 mg/kg) or vehicle (corn oil) from the postnatal 7 days at 3-day intervals for 14 days. The immunohistochemical assay shows that the expression of TFRC and COX2 is higher in Bnc1tr/tr control mouse ovaries than in Bnc1+/+ control mouse ovaries. Intriguingly, VP treatment partially rescues TFRC and COX2 expression in Bnc1tr/tr mouse ovaries.
-
Hepatology
TNFAIP3 Interacting Protein 3 Is an Activator of Hippo-YAP Signaling Protecting Against Hepatic Ischemia/Reperfusion Injury. [Abstract]2021 Oct;74(4):2133-2153. PMID: 34133792
Verteporfin purchased from MedChemExpress. Usage Cited in: Hepatology. 2021 Oct;74(4):2133-2153. [Abstract]
The expression levels of Hippo-YAP signaling downstream regenerative genes (Ctgf, Ankrd1 and Cyr61) are effectively inhibited by Verteporfin (VP; 100 µM) compared to their expression in the blank control group.
Verteporfin purchased from MedChemExpress. Usage Cited in: Hepatology. 2021 Oct;74(4):2133-2153. [Abstract]
Compared to cell viability in the vehicle control group, Verteporfin (VP; 100 µM) markedly impairs cell viability assayed by JC-1 staining and CCK-8.
Verteporfin purchased from MedChemExpress. Usage Cited in: Hepatology. 2021 Oct;74(4):2133-2153. [Abstract]
Compared to cell viability in the vehicle control group, Verteporfin (VP; 100 µM) markedly impairs cell viability assayed by JC-1 staining and CCK-8.
Verteporfin purchased from MedChemExpress. Usage Cited in: Hepatology. 2021 Oct;74(4):2133-2153. [Abstract]
The protective effects of TNIP3 against cell inflammation and cell death were largely abolished by Verteporfin (VP; 100 µM) administration.
-
Hepatology
PDLIM1 Inhibits Tumor Metastasis Through Activating Hippo Signaling in Hepatocellular Carcinoma. [Abstract]2020 May;71(5):1643-1659. PMID: 31509262 -
ACS Nano
2024 Aug 13;18(32):21009-21023. PMID: 39087239 -
ACS Nano
Tumor Vessel Targeted Self-Assemble Nanoparticles for Amplification and Prediction of the Embolization Effect in Hepatocellular Carcinoma. [Abstract]2020 Nov 24;14(11):14907-14918. PMID: 33111520 -
J Adv Res
Dysregulated ITGA3/FAK/YAP axis mediates impaired alveolar type II epithelial cells function in COPD. [Abstract]2025 Nov 19:S2090-1232(25)00929-4. PMID: 41270956 -
Redox Biol
Hippo pathway activation mediates cardiomyocyte ferroptosis to promote dilated cardiomyopathy through downregulating NFS1. [Abstract]2025 May:82:103597. PMID: 40107016 -
Redox Biol
2020 Oct;37:101745. PMID: 33099216 -
Mol Cell
2019 Jan 3;73(1):7-21.e7. PMID: 30472188
Verteporfin purchased from MedChemExpress. Usage Cited in: Mol Cell. 2019 Jan 3;73(1):7-21.e7. [Abstract]
Control low metastatic MDA-MB-231 cells or cells overexpressing OTUB2-WT, pretreated with or without Verteporfin (VP, 10 µM) are intracardially injected into nude mice.
-
-
Gut Microbes
Fusobacterium nucleatum induces chemoresistance in colorectal cancer by inhibiting pyroptosis via the Hippo pathway. [Abstract]2024 Jan-Dec;16(1):2333790. PMID: 38533566 -
J Nanobiotechnology
Stepwise-targeting and hypoxia-responsive liposome AMVY@NPs carrying siYAP and verteporfin for glioblastoma therapy. [Abstract]2024 Aug 20;22(1):495. PMID: 39164753 -
Theranostics
Single-cell transcriptomic profiling provides insights into the toxic effects of Zearalenone exposure on primordial follicle assembly. [Abstract]2021 Mar 5;11(11):5197-5213. PMID: 33859742 -
Genes Dis
PCK1 attenuates tumor stemness via activating the Hippo signaling pathway in hepatocellular carcinoma. [Abstract]2023 Sep 16;11(4):101114. PMID: 38560500 -
Genes Dis
2021 Nov 19;9(6):1701-1715. PMID: 36157502 -
J Exp Clin Cancer Res
Bifidobacterium adolescentis induces Decorin+ macrophages via TLR2 to suppress colorectal carcinogenesis. [Abstract]2023 Jul 18;42(1):172. PMID: 37464382 -
J Exp Clin Cancer Res
RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast Cancer. [Abstract]2022 Dec 29;41(1):364. PMID: 36581998 -
J Exp Clin Cancer Res
Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC). [Abstract]2022 Jun 3;41(1):193. PMID: 35655319 -
J Exp Clin Cancer Res
Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids. [Abstract]2020 Jan 28;39(1):22. PMID: 31992334 -
Adv Sci (Weinh)
Genome-Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma. [Abstract]2026 May 26:e15158. PMID: 42189126 -
Adv Sci (Weinh)
2025 May 20:e2416489. PMID: 40390546 -
Adv Sci (Weinh)
2025 May;12(17):e2410909. PMID: 39921490 -
Adv Sci (Weinh)
2024 Apr;11(16):e2308531. PMID: 38380551 -
MedComm
Inhibition of YAP1 activity ameliorates acute lung injury through promotion of M2 macrophage polarization. [Abstract]2023 Jun 5;4(3):e293. PMID: 37287755 -
Adv Sci (Weinh)
Pharmacological Perturbation of Mechanical Contractility Enables Robust Transdifferentiation of Human Fibroblasts into Neurons. [Abstract]2022 May;9(13):e2104682. PMID: 35240008 -
Sci Adv
Combinatorial screening of biochemical and physical signals for phenotypic regulation of stem cell-based cartilage tissue engineering. [Abstract]2020 May 22;6(21):eaaz5913. PMID: 32494742 -
Cell Death Differ
Collagen I-DDR1 signaling promotes hepatocellular carcinoma cell stemness via Hippo signaling repression. [Abstract]2023 Jul;30(7):1648-1665. PMID: 37117273 -
Biomaterials
Chemiluminescence resonance energy transfer-based immunostimulatory nanoparticles for sonoimmunotherapy. [Abstract]2022 Apr:283:121466. PMID: 35286853 -
Neuro Oncol
FRK inhibits glioblastoma progression via phosphorylating YAP and inducing its ubiquitylation and degradation by Siah1. [Abstract]2022 Dec 1;24(12):2107-2120. PMID: 35723276 -
Mol Biomed
Lactate-driven pyrimidine synthesis promotes ferroptosis resistance in hepatocellular carcinoma. [Abstract]2026 Apr 17;7(1):53. PMID: 41996004 -
Cell Death Dis
Subclonal β-catenin/YAP signaling heterogeneity accelerates ovarian cancer metastasis through a senescence-associated secretory phenotype. [Abstract]2026 Apr 23;17(1):539. PMID: 42026023 -
Cell Death Dis
Generation of proliferative hESC-derived grape-clustered hepatocyte organoids with multipolar architecture as regenerative counterpart via synergy of YAP and IGF2 pathways. [Abstract]2026 Mar 26;17(1):381. PMID: 41888105 -
Cell Death Dis
Positive feedback regulation between USP8 and Hippo/YAP axis drives triple-negative breast cancer progression. [Abstract]2026 Jan 21;17(1):98. PMID: 41565619 -
Cell Death Dis
VIRMA/IGF2BP3-mediated ANLN upregulation promotes intrahepatic cholangiocarcinoma growth by forming a positive feedback loop with RhoA/YAP1/TEAD1 signaling pathway. [Abstract]2026 Jan 9;17(1):20. PMID: 41513610 -
Cell Death Dis
TET2 orchestrates YAP signaling to potentiate targetable vulnerability in hepatocellular carcinoma. [Abstract]2025 Jun 5;16(1):438. PMID: 40473594 -
Cell Death Dis
2025 May 28;16(1):422. PMID: 40436845 -
Cell Death Dis
YAP1 facilitates the pathogenesis of psoriasis via modulating keratinocyte proliferation and inflammation. [Abstract]2025 Mar 19;16(1):186. PMID: 40108109 -
Cell Death Dis
Enhanced ferroptosis sensitivity promotes the formation of highly myopic cataract via the DDR2-Hippo pathway. [Abstract]2025 Feb 3;16(1):64. PMID: 39900894 -
Cell Death Dis
2025 Jan 14;16(1):17. PMID: 39809787 -
Cell Death Dis
2022 Oct 1;13(10):839. PMID: 36180487 -
Cell Death Dis
P130cas-FAK interaction is essential for YAP-mediated radioresistance of non-small cell lung cancer. [Abstract]2022 Sep 10;13(9):783. PMID: 36088346 -
Cell Death Dis
Photodynamic therapy induces autophagy-mediated cell death in human colorectal cancer cells via activation of the ROS/JNK signaling pathway. [Abstract]2020 Oct 31;11(10):938. PMID: 33130826 -
Small
Temperature-Programmable Deformable Microneedles for Scar-Free Healing of Infective Wounds via Sensory Nerve Regeneration. [Abstract]2025 Apr 3:e2501491. PMID: 40178015 -
Small
A Self-Amplifying Photodynamic Biomedicine for Cascade Immune Activation Against Triple-Negative Breast Cancer. [Abstract]2025 Jan 23:e2410214. PMID: 39846288 -
Cancer Lett
NONO promotes gallbladder cancer cell proliferation by enhancing oncogenic RNA splicing of DLG1 through interaction with IGF2BP3/RBM14. [Abstract]2024 Apr 10:587:216703. PMID: 38341127 -
Cancer Lett
2022 Aug 10:541:215749. PMID: 35597479 -
Small
Biomimetic Activator of Sonodynamic Ferroptosis Amplifies Inherent Peroxidation for Improving the Treatment of Breast Cancer. [Abstract]2022 Mar;18(12):e2106568. PMID: 35092152 -
Small
Mechanical Cues Regulating Proangiogenic Potential of Human Mesenchymal Stem Cells through YAP-Mediated Mechanosensing. [Abstract]2020 May 17;e2001837. PMID: 32419312 -
Cell Commun Signal
2024 May 16;22(1):277. PMID: 38755629 -
Cell Commun Signal
Regulation of the integrin αVβ3- actin filaments axis in early osteogenic differentiation of human mesenchymal stem cells under cyclic tensile stress. [Abstract]2023 Oct 30;21(1):308. PMID: 37904190 -
Cell Commun Signal
Receptor activity-modifying protein 1 regulates mouse skin fibroblast proliferation via the Gαi3-PKA-CREB-YAP axis. [Abstract]2022 Apr 12;20(1):52. PMID: 35413847 -
Phytomedicine
Usenamine a potentiates anti-CRC activity of sorafenib by inducing autophagy and inhibiting YAP pathway through targeting SOD2. [Abstract]2026 Jun:155:158086. PMID: 41861687 -
Phytomedicine
Celastrol attenuates ferroptosis-mediated intestinal ischemia/reperfusion-induced acute lung injury via Hippo-YAP signaling. [Abstract]2025 May 17:143:156865. PMID: 40414049 -
Phytomedicine
Curzerene suppresses epithelial-mesenchymal transition in gastric precancerous lesion cells through targeted regulation of YAP via the long non-coding RNA AFAP1-AS1. [Abstract]2025 May 21:143:156879. PMID: 40414046 -
Phytomedicine
Naringenin alleviates intestinal ischemia/reperfusion injury by inhibiting ferroptosis via targeting YAP/STAT3 signaling axis. [Abstract]2024 Dec:135:156095. PMID: 39383632 -
Phytomedicine
Single-cell RNA transcriptomics reveals Du-Zhong-Wan promotes osteoporotic fracture healing via YAP/β-catenin/VEGF axis in BMSCs. [Abstract]2024 Dec:135:155572. PMID: 39366157 -
Phytomedicine
TKF, a mexicanolide-type limonoid derivative, suppressed hepatic stellate cells activation and liver fibrosis through inhibition of the YAP/Notch3 pathway. [Abstract]2022 Dec:107:154466. PMID: 36182796 -
Phytomedicine
Dihydroartemisinin reduced lipid droplet deposition by YAP1 to promote the anti-PD-1 effect in hepatocellular carcinoma. [Abstract]2022 Feb:96:153913. PMID: 35026515 -
Phytomedicine
Physalin D attenuates hepatic stellate cell activation and liver fibrosis by blocking TGF-β/Smad and YAP signaling. [Abstract]2020 Nov:78:153294. PMID: 32771890 -
Mater Today Bio
ROS-responsive drug delivery system with enhanced anti-angiogenic and anti-inflammatory properties for neovascular age-related macular degeneration therapy. [Abstract]2025 Apr 10:32:101757. PMID: 40290884 -
Mater Today Bio
Turning sublimed sulfur and bFGF into a nanocomposite to accelerate wound healing via co-activate FGFR and Hippo signaling pathway. [Abstract]2024 May 27:26:101104. PMID: 38952539 -
Adv Healthc Mater
2022 Nov;11(21):e2201032. PMID: 36052735 -
Acta Biomater
Nuclear compression overrides matrix softness to regulate stem cell fate through actomyosin-driven YAP mechanotransduction. [Abstract]2026 Jun:216:287-297. PMID: 42035970 -
Acta Biomater
Differential traction forces underlie spatial heterogeneity in early differentiation of human embryonic stem cell clones. [Abstract]2026 May 14:S1742-7061(26)00314-4. PMID: 42140565 -
Acta Pharmacol Sin
Targeting the 5-HT1B-YAP positive feedback loop protects against disturbed flow-induced atherogenesis in mice. [Abstract]2025 Nov 1. PMID: 41176538 -
Acta Biomater
Substrate stiffness regulates the proliferation and inflammation of chondrocytes and macrophages through exosomes. [Abstract]2025 Jan 15:192:77-89. PMID: 39662715 -
Acta Pharmacol Sin
Activation of MST1 protects filtration barrier integrity of diabetic kidney disease in mice through restoring the tight junctions of glomerular endothelial cells. [Abstract]2025 May;46(5):1345-1360. PMID: 39643641 -
Acta Pharmacol Sin
Adaptor protein CEMIP reduces the chemosensitivity of small cell lung cancer via activation of an SRC-YAP oncogenic module. [Abstract]2024 Dec;45(12):2657-2671. PMID: 39043968 -
Cell Death Discov
YAP nuclear translocation induced by HIF-1α prevents DNA damage under hypoxic conditions. [Abstract]2023 Oct 20;9(1):385. PMID: 37863897 -
Cell Death Discov
2023 Sep 9;9(1):339. PMID: 37689711 -
Cell Death Discov
Verteporfin reverses progestin resistance through YAP/TAZ-PI3K-Akt pathway in endometrial carcinoma. [Abstract]2023 Jan 25;9(1):30. PMID: 36693834 -
Cell Death Discov
Clock-modified mesenchymal stromal cells therapy rescues molecular circadian oscillation and age-related bone loss via miR142-3p/Bmal1/YAP signaling axis. [Abstract]2022 Mar 12;8(1):111. PMID: 35279674 -
-
J Orthop Translat
Oxidative stress activates YAP/TEAD1/NCOA4 axis to promote ferroptosis of endplate chondrocytes and aggravate intervertebral disc degeneration. [Abstract]2025 Jul 12:54:8-25. PMID: 40688343 -
J Transl Med
LncRNA H19-rich extracellular vesicles derived from gastric cancer stem cells facilitate tumorigenicity and metastasis via mediating intratumor communication network. [Abstract]2023 Apr 1;21(1):238. PMID: 37005676
Verteporfin purchased from MedChemExpress. Usage Cited in: J Transl Med. 2023 Apr 1;21(1):238. [Abstract]
Verteporfin (13.9 µM; 10 µg/mL; 24 h) decreases the expression of YAP and CDX2 in NSCCs.
-
Proc Natl Acad Sci U S A
2024 Sep 24;121(39):e2403062121. PMID: 39302966 -
Dev Cell
Conserved signals control self-organization and symmetry breaking of murine bilayered epithelia during development and regeneration. [Abstract]2025 Jun 25:S1534-5807(25)00362-4. PMID: 40592344 -
Oncogene
RANBP1 promotes colorectal cancer progression by regulating pre-miRNA nuclear export via a positive feedback loop with YAP. [Abstract]2022 Feb;41(7):930-942. PMID: 34615998 -
Apoptosis
Sirtuin 7 ameliorates cuproptosis, myocardial remodeling and heart dysfunction in hypertension through the modulation of YAP/ATP7A signaling. [Abstract]2024 Dec;29(11-12):2161-2182. PMID: 39394530 -
Int J Nanomedicine
High-Performance Photodynamic Therapy of Tongue Squamous Cell Carcinoma with Multifunctional Nano-Verteporfin. [Abstract]2024 Mar 13:19:2611-2623. PMID: 38505166 -
Int J Nanomedicine
Nano-Photosensitizer Directed Targeted Phototherapy Effective Against Oral Cancer in Animal Model. [Abstract]2023 Nov 1:18:6185-6198. PMID: 37933297 -
Neural Regen Res
Salsolinol as an RNA m6A methylation inducer mediates dopaminergic neuronal death by regulating YAP1 and autophagy. [Abstract]2025 Mar 1;20(3):887-899. PMID: 38886960 -
Mol Med
Piezo1 promotes intervertebral disc degeneration through the Ca2+/F-actin/Yap signaling axis. [Abstract]2025 Mar 8;31(1):90. PMID: 40057686 -
Cell Mol Gastroenterol Hepatol
EP300/YAP1-SERPINE1 Signaling Regulates Ductular Reaction and Liver Fibrosis in Biliary Atresia. [Abstract]2025 Sep 22:101640. PMID: 40992734 -
Biofabrication
High-yield extracellular vesicle production from HEK293T cells encapsulated in 3D auxetic scaffolds with cyclic mechanical stimulation for effective drug carrier systems. [Abstract]2024 Sep 2;16(4). PMID: 39173665 -
Antioxidants (Basel)
YAP Inhibition Alleviates Simulated Microgravity-Induced Mesenchymal Stem Cell Senescence via Targeting Mitochondrial Dysfunction. [Abstract]2023 Apr 24;12(5):990. PMID: 37237856 -
Free Radic Biol Med
Raddeanin A induces ferroptosis by targeting VEPH1 in a cisplatin-resistant epithelial ovarian cancer cell line. [Abstract]2026 Aug 16:252:55-68. PMID: 41997548 -
Free Radic Biol Med
Hypothermic machine perfusion attenuates DCD liver ischemia reperfusion injury via the YAP1/P53-mediated micromitophagy pathway. [Abstract]2026 Mar 25:250:174-188. PMID: 41895416 -
Free Radic Biol Med
YAP-mediated DDX3X confers resistance to ferroptosis in breast cancer cells by reducing lipid peroxidation. [Abstract]2025 May:232:330-339. PMID: 40089076 -
J Anim Sci Biotechnol
Kynurenine promotes porcine intestinal epithelial cell proliferation by activating the AHR-MST1-YAP1 axis. [Abstract]2026 Mar 17;17(1):50. PMID: 41845541 -
EMBO Mol Med
Corneal biomechanical cues mediated by PAI-2: the origin of PM2.5-induced corneal disease. [Abstract]2025 Dec 1. PMID: 41326717 -
Clin Transl Med
JCAD deficiency delayed liver regenerative repair through the Hippo-YAP signalling pathway. [Abstract]2024 Mar;14(3):e1630. PMID: 38509842 -
J Genet Genomics
Cdx1b protects intestinal cell fate by repressing signaling networks for liver specification. [Abstract]2022 Dec;49(12):1101-1113. PMID: 36460297 -
Clin Transl Med
Tumor-derived exosomal miR-19b-3p facilitates M2 macrophage polarization and exosomal LINC00273 secretion to promote lung adenocarcinoma metastasis via Hippo pathway. [Abstract]2021 Sep;11(9):e478. PMID: 34586722 -
EMBO Mol Med
2018 Nov;10(11). pii: e8699. PMID: 30143543 -
ACS Appl Mater Interfaces
Hydrogel Enhanced Organoid Multidirectional Differentiation via Yap/Tead4 Mechanotransduction for Accelerated Tissue Regeneration. [Abstract]2025 Jul 2;17(26):37601-37616. PMID: 40550785 -
Stem Cell Res Ther
Regulation of the integrin αVβ3- actin filaments axis in early osteogenesis of human fibroblasts under cyclic tensile stress. [Abstract]2021 Oct 7;12(1):523. PMID: 34620239 -
Cell Rep
Shear stress-induced Piezo1 activates CD99L2 to facilitate the initiation of blood circulation. [Abstract]2026 Mar 30;45(4):117200. PMID: 41915472 -
Cell Prolif
Targeting ROCK1/YAP1 Axis Ameliorates Inflammation-Induced Prostatic Hyperplasia via Stabilising SIRT1-Dependent Mitochondrial Dynamics. [Abstract]2025 Jul 4:e70085. PMID: 40616266 -
Cell Prolif
2024 Aug;57(8):e13640. PMID: 38556840 -
Cell Prolif
FGF6 promotes cardiac repair after myocardial infarction by inhibiting the Hippo pathway. [Abstract]2022 May;55(5):e13221. PMID: 35355356 -
Br J Pharmacol
Diminished nuclear-localized β-adrenoceptor signalling activates YAP to promote kidney fibrosis in diabetic nephropathy. [Abstract]2024 Oct 2. PMID: 39359016 -
Cell Syst
A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. [Abstract]2018 Apr 25;6(4):424-443.e7. PMID: 29655704 -
Sci Signal
PARP1-mediated PARylation of TEAD4 stabilizes the YAP1-TEAD4 complex and promotes growth and immune evasion in breast cancer cells. [Abstract]2025 Oct 21;18(909):eadx2532. PMID: 41118450 -
Cancer Cell Int
Novel sequential therapy with metformin enhances the effects of cisplatin in testicular germ cell tumours via YAP1 signalling. [Abstract]2022 Mar 9;22(1):113. PMID: 35264157 -
NPJ Regen Med
The common YAP activation mediates corneal epithelial regeneration and repair with different-sized wounds. [Abstract]2021 Mar 26;6(1):16. PMID: 33772031 -
Cancer Cell Int
Identification of glycolysis related pathways in pancreatic adenocarcinoma and liver hepatocellular carcinoma based on TCGA and GEO datasets. [Abstract]2021 Feb 19;21(1):128. PMID: 33607990 -
Cancer Cell Int
YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway. [Abstract]2019 Jul 12:19:179. PMID: 31337986 -
Redox Rep
The hippo-YAP1/TEAD1-SLC7A5 axis: uncovering a novel therapeutic target for oxalate-induced renal tubular ferroptosis. [Abstract]2026 Dec;31(1):2643967. PMID: 41833934 -
Mol Cancer Ther
Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. [Abstract]2025 Apr 28:OF1-OF13. PMID: 40293279 -
Neurosci Bull
Neuronal and Glial YAP/TAZ in the Spinal Cord Contribute to the Development of Bone Cancer Pain in Mice. [Abstract]2026 Mar 22. PMID: 41866450 -
JCI Insight
YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis. [Abstract]2024 Dec 20;9(24):e178535. PMID: 39704172 -
Biomater Adv
Synergistic photodynamic therapy and IDO inhibition via a self-assembled nanomedicine potentiates PD-L1 blockade in gastrointestinal cancers. [Abstract]2026 Aug:185:214849. PMID: 41946114 -
Biomater Adv
Hippo/YAP1 inhibition by verteporfin attenuates osteophyte formation in a mouse surgical osteoarthritis model. [Abstract]2023 Jun:149:213413. PMID: 37027967 -
J Dent Res
2019 Jul;98(8):920-929. PMID: 31282845 -
Biochem Pharmacol
Dexmedetomidine suppresses ferritinophagy-mediated ferroptosis in myocardial ischemia/reperfusion injury via the YAP1/NCOA4 pathway. [Abstract]2026 Jun:248:117837. PMID: 41724278 -
Cell Biosci
TRIM16 mediates YAP1 K63-linked ubiquitination to alleviate sepsis-induced acute liver injury through YAP/Nrf2 axis in mice. [Abstract]2025 Dec 23;16(1):7. PMID: 41437125 -
Biochem Pharmacol
Silibinin inhibits F-actin assembly leading to G2/M cell cycle arrest in human breast cancer cells - is targeted therapy on the horizon?. [Abstract]2026 Feb:244:117602. PMID: 41349910 -
Biochem Pharmacol
Circ_0057582 inhibits breast cancer progression via hnRNPF/YAP/SOX9 axis and M2 polarization in TAMs by autophagic degradation of ISG15. [Abstract]2026 Jan;243(Pt 2):117543. PMID: 41241017 -
Biochem Pharmacol
2025 Jul 19:241:117185. PMID: 40692108 -
Biochem Pharmacol
Upregulation of TRIM16 mitigates doxorubicin-induced cardiotoxicity by modulating TAK1 and YAP/Nrf2 pathways in mice. [Abstract]2024 Feb:220:116009. PMID: 38154547 -
Cell Mol Life Sci
Omentin-1 drives cardiomyocyte cell cycle arrest and metabolic maturation by interacting with BMP7. [Abstract]2023 Jun 21;80(7):186. PMID: 37344704 -
J Bone Miner Res
Modification of COL1A1 in Autologous Adipose Tissue-Derived Progenitor Cells Rescues the Bone Phenotype in a Mouse Model of Osteogenesis Imperfecta. [Abstract]2021 Aug;36(8):1521-1534. PMID: 33950576 -
Mol Ther Nucleic Acids
Piezo 1 activation facilitates cholangiocarcinoma metastasis via Hippo/YAP signaling axis. [Abstract]2021 Feb 26:24:241-252. PMID: 33767919 -
Cell Biosci
Arsenic nano complex induced degradation of YAP sensitized ESCC cancer cells to radiation and chemotherapy. [Abstract]2020 Dec 22;10(1):146. PMID: 33353561 -
Int Endod J
2026 Jun 2. PMID: 42227345 -
Life Sci
Compressive stress induces cartilage endplate degeneration through the Piezo1/YAP-TEAD/NLRP3 axis. [Abstract]2026 Mar 1:388:124195. PMID: 41506536 -
Life Sci
Dapagliflozin delays renal fibrosis in diabetic kidney disease by inhibiting YAP/TAZ activation. [Abstract]2023 Jun 1:322:121671. PMID: 37023953 -
Food Funct
Daidzein alleviates CCl4- and BDL-induced liver fibrosis via suppressing the integrin alphaVbeta1/YAP signaling. [Abstract]2025 Jun 16;16(12):4822-4836. PMID: 40407304 -
J Cell Biol
Irg1l regulates neuromast size via metabolic reprogramming to promote supporting cell proliferation. [Abstract]2025 Dec 1;224(12):e202501122. PMID: 41147954 -
Transl Res
Neutrophil Extracellular Traps Induce Abdominal Aortic Aneurysm Formation by Promoting the Synthetic and Proinflammatory Smooth Muscle Cell Phenotype via Hippo-YAP Pathway. [Abstract]2023 May:255:85-96. PMID: 36435329 -
Acs Biomater Sci Eng
Matrix Stiffness Potentiates Stemness of Liver Cancer Stem Cells Possibly via the Yes-Associated Protein Signal. [Abstract]2022 Feb 14;8(2):598-609. PMID: 35084830 -
Cells
Wnt5A and TGFβ1 Converges through YAP1 Activity and Integrin Alpha v Up-Regulation Promoting Epithelial to Mesenchymal Transition in Ovarian Cancer Cells and Mesothelial Cell Activation. [Abstract]2022 Jan 11;11(2):237. PMID: 35053353 -
Cells
IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells. [Abstract]2020 Apr 18;9(4):1010. PMID: 32325700 -
Colloids Surf B Biointerfaces
Oxygen-boosted nanodrug for amplified ferroptosis-photodynamic immunotherapy together with PD-1 checkpoint blockade against triple-negative breast cancer. [Abstract]2025 Jul 17:255:114963. PMID: 40695078 -
Cancer Immunol Immunother
MS4A1 regulates M1-polarized tumor-associated macrophage infiltration, angiogenesis, and cancer progression through the HIPPO pathway in lung adenocarcinoma. [Abstract]2025 Nov 3;74(12):356. PMID: 41182411 -
Eur J Pharmacol
Melatonin postconditioning attenuates myocardial ischemia/reperfusion injury by activating YAP to decrease DRP1-mediated mitochondrial fission. [Abstract]2026 Apr 15:1021:178827. PMID: 41912007 -
Respir Res
2025 Feb 12;26(1):51. PMID: 39939959 -
Pharmaceuticals (Basel)
JTE-013 Alleviates Pulmonary Fibrosis by Affecting the RhoA/YAP Pathway and Mitochondrial Fusion/Fission. [Abstract]2023 Oct 12;16(10):1444. PMID: 37895915 -
Biomolecules
Mitophagy Activation via the YAP/Parkin Pathway Underlies the Neuroprotective Action of Tetramethylpyrazine in Cerebral Ischemia/Reperfusion Injury. [Abstract]2026 Mar 13;16(3):429. PMID: 41897365 -
Int J Mol Sci
MED12 Dictates Epithelial Ovarian Cancer Cell Ferroptosis Sensitivity via YAP-TEAD1 Signaling. [Abstract]2026 Jan 20;27(2):1020. PMID: 41596664 -
ACS Appl Bio Mater
Vanadium Single-Atom Nanozyme Boosts Cuproptosis/Ferroptosis/Apoptosis Combined with Photothermal-Enhanced Tumor Therapy through Dual Catalytic Activity. [Abstract]2025 Oct 25. PMID: 41137854 -
Int J Mol Sci
2025 Sep 18;26(18):9129. PMID: 41009691 -
Int Immunopharmacol
Calcitonin gene-related peptide-modulated macrophage phenotypic alteration regulates angiogenesis in early bone healing. [Abstract]2024 Mar 30:130:111766. PMID: 38452411 -
Int Immunopharmacol
The role of 14-3-3 in the progression of vascular inflammation induced by lipopolysaccharide. [Abstract]2023 Jun:119:110220. PMID: 37104914 -
Int Immunopharmacol
TRIP6 accelerates the proliferation and migration of fetal airway smooth muscle cells by enhancing YAP activation. [Abstract]2020 Mar 6;82:106366. PMID: 32151960 -
Neurochem Int
Downregulation of Preso protects against ischemic/reperfusion-mediated neuronal injury through regulating PSD95-nNOS/YAP pathways. [Abstract]2023 Oct:169:105586. PMID: 37442439 -
J Periodontal Res
Tooth Movement Modulation and Root Protection via Piezo1-Mediated Production of Superoxide Dismutase 3. [Abstract]2026 Jan 24. PMID: 41578937 -
-
BMC Biol
Rotating culture regulates the formation of HepaRG-derived liver organoids via YAP translocation. [Abstract]2024 Nov 15;22(1):262. PMID: 39548509 -
J Pathol
Yes-associated protein regulates the hepatoprotective effect of vitamin D receptor activation through promoting adaptive bile duct remodeling in cholestatic mice. [Abstract]2021 Sep;255(1):95-106. PMID: 34156701 -
J Ovarian Res
FTO attenuates the cytotoxicity of cisplatin in KGN granulosa cell-like tumour cells by regulating the Hippo/YAP1 signalling pathway. [Abstract]2024 Mar 15;17(1):62. PMID: 38491479 -
Front Cell Dev Biol
2021 May 12:9:639111. PMID: 34055773 -
Int Dent J
2026 Jun 27;76(5):109698. PMID: 42364415 -
Chem Biol Interact
Integrated network pharmacology, bioinformatics, and experiment analysis to decipher the molecular mechanism of Salidroside on Gastric cancer via targeting NCOA4-mediated ferritinophagy. [Abstract]2024 Dec 31:111368. PMID: 39746501 -
Biofactors
2024 Nov-Dec;50(6):1113-1133. PMID: 38655699 -
Biochim Biophys Acta Mol Basis Dis
P75NTR regulates autophagy through the YAP-mTOR pathway to increase the proliferation of interfollicular epidermal cells and promote wound healing in diabetic mice. [Abstract]2024 Mar;1870(3):167012. PMID: 38176461 -
Mol Med Rep
Determination of the migration effect and molecular docking of verteporfin in different subtypes of breast cancer cells. [Abstract]2020 Nov;22(5):3955-3961. PMID: 32901856 -
Biochim Biophys Acta Mol Basis Dis
Matrix stiffness modulates ILK-mediated YAP activation to control the drug resistance of breast cancer cells. [Abstract]2020 Mar 1;1866(3):165625. PMID: 31785406 -
Cancer Sci
Decreased Expression of FAT4 Promotes Multiple Myeloma Proliferation and Migration by Targeting the Hippo/YAP Pathway. [Abstract]2026 Jul;117(7):1883-1893. PMID: 42023818 -
Cancer Sci
Resveratrol as a Novel YAP Inhibitor Targeting Glioblastoma Progression and Sensitizing to Chemotherapy. [Abstract]2026 Mar;117(3):695-710. PMID: 41518046 -
Sci Rep
The TRPV4-YAP axis mediates cytoskeletal and extracellular matrix remodeling in trabecular meshwork cells as a novel glaucoma mechanism. [Abstract]2025 Nov 24;15(1):41644. PMID: 41286165 -
Sci Rep
ID1 promotes the progression of esophageal cancer via modulating PTEN/YAP/galectin-3 signaling pathway induced proliferation and immune suppression. [Abstract]2025 Oct 6;15(1):34796. PMID: 41053273 -
Sci Rep
TGFβ1 accelerated the progression of diabetic nephropathy via up-regulating BRD4/Notch1/YAP signaling induced fibrosis and proliferation in fibroblasts. [Abstract]2025 Jul 13;15(1):25338. PMID: 40653516 -
Am J Pathol
Fibrotic matrix induces mesenchymal transformation of epithelial cells in oral submucous fibrosis. [Abstract]2023 Sep;193(9):1208-1222. PMID: 37328100 -
Mediators Inflamm
Inverse Agonist of Retinoid-Related Orphan Receptor-Alpha Prevents Apoptosis and Degeneration in Nucleus Pulposus Cells via Upregulation of YAP. [Abstract]2021 Jul 28:2021:9954909. PMID: 34366712 -
Ultrasonics
High-frequency ultrasound imaging for monitoring the function of meningeal lymphatic system in mice. [Abstract]2023 May:131:106949. PMID: 36773481 -
Cancers (Basel)
Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma. [Abstract]2023 Jan 31;15(3):886. PMID: 36765842 -
Mol Cell Biochem
HIRA promotes osteogenic differentiation of BMSCs and ameliorates osteoporosis by mediating M2 polarization of macrophages through the YAP1/β-catenin pathway. [Abstract]2026 Jun;481(6):2449-2466. PMID: 42048035 -
J Cell Mol Med
GPSM2 Promotes Pancreatic Cancer Progression Through METTL3-Mediated m6A Modification of YAP1 mRNA. [Abstract]2026 Jun;30(11):e71224. PMID: 42231052 -
Cell Signal
Cell-type specific contribution of KLF4 to fibrotic nephropathy in tubular epithelium and fibroblast. [Abstract]2026 Jul:143:112459. PMID: 41785980 -
Virol Sin
2025 Aug;40(4):658-668. PMID: 40701343 -
Cell Signal
Inhibition of YAP/TAZ pathway contributes to the cytotoxicity of silibinin in MCF-7 and MDA-MB-231 human breast cancer cells. [Abstract]2024 Jul:119:111186. PMID: 38643945 -
Oncol Rep
YAP activation attenuates toxicarioside G‑induced lethal autophagy arrest in SW480 colorectal cancer cells. [Abstract]2021 Oct;46(4):224. PMID: 34458926 -
Oncol Rep
Platelet‑derived growth factor‑BB mediates pancreatic cancer malignancy via regulation of the Hippo/Yes‑associated protein signaling pathway. [Abstract]2021 Jan;45(1):83-94. PMID: 33416116 -
J Cell Mol Med
Dabigatran ameliorates airway smooth muscle remodeling in asthma by modulating Yes-associated protein. [Abstract]2020 Jul;24(14):8179-8193. PMID: 32542982 -
iScience
Targeting Rap1-YAP1 mechanosignaling for ameliorating acute IOP elevation-induced trabecular meshwork dysfunction. [Abstract]2026 Jun 5;29(6):116268. PMID: 42291280 -
Neurochem Res
2025 Dec 29;51(1):24. PMID: 41460540 -
iScience
2025 Jan 21;28(2):111854. PMID: 39991547 -
Acta Biochim Biophys Sin (Shanghai)
Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis. [Abstract]2024 Apr 25;56(4):621-633. PMID: 38516704 -
Front Cell Neurosci
ROCK Inhibitor Y27632 Induced Morphological Shift and Enhanced Neurite Outgrowth-Promoting Property of Olfactory Ensheathing Cells via YAP-Dependent Up-Regulation of L1-CAM. [Abstract]2018 Dec 11:12:489. PMID: 30618636
Verteporfin purchased from MedChemExpress. Usage Cited in: Front Cell Neurosci. 2018 Dec 11:12:489. [Abstract]
OECs are treated with vehicle (0.1% DMSO), Y27632 (10 μM) or verteporfin (5 μM) for 24 h and performed WB analysis.
-
Biochim Biophys Acta Mol Cell Res
Development of a TEAD-independent reporter system for specific and sensitive measurement of YAP/TAZ activity. [Abstract]2026 Mar;1873(3):120111. PMID: 41534572 -
FASEB J
Matrix Stiffening-Induced SLIT3 Activation in Chondrocytes Drives Cartilage Degradation and Angiogenesis in Temporomandibular Joint Osteoarthritis. [Abstract]2025 Aug 31;39(16):e70936. PMID: 40817785 -
FASEB J
The aryl hydrocarbon receptor affects the inflammatory response of bone marrow mesenchymal stem cell via the hippo-YAP pathway to exacerbate systemic lupus erythematosus. [Abstract]2025 Feb 28;39(4):e70410. PMID: 39985295 -
FASEB J
Extracellular HSP90 promotes differentiation of lens epithelial cells to fiber cells by activating LRP1-YAP-PROX1 axis. [Abstract]2023 Feb;37(2):e22783. PMID: 36705056 -
J Biol Chem
2024 Jul 1:107512. PMID: 38960037 -
J Biol Chem
Upregulation of CYR61 by TGF-β and YAP signaling exerts a counter-suppression of hepatocellular carcinoma. [Abstract]2024 Apr;300(4):107208. PMID: 38521502 -
J Biol Chem
Verteporfin is a substrate-selective γ-secretase inhibitor that binds the amyloid precursor protein transmembrane domain. [Abstract]2022 Apr;298(4):101792. PMID: 35247387 -
Development
2025 Jun 16:dev.204483. PMID: 40521668 -
Naunyn Schmiedebergs Arch Pharmacol
The targeting of YAP by kaempferol regulates bone homeostasis and improves osteoporosis in rats. [Abstract]2025 Apr 10. PMID: 40208316 -
J Biomed Mater Res A
Elastic modulus of hydrogel regulates osteogenic differentiation via liquid-liquid phase separation of YAP. [Abstract]2023 Nov;111(11):1781-1797. PMID: 37494632 -
J Anim Sci
Prolactin promotes crop epithelial proliferation of domestica pigeon (Columba livia) through the Hippo signaling pathway. [Abstract]2023 Jan 3:101:skad312. PMID: 37721785 -
Mol Immunol
Blockade of YAP alleviates hepatic fibrosis through accelerating apoptosis and reversion of activated hepatic stellate cells. [Abstract]2019 Mar:107:29-40. PMID: 30639476
Verteporfin purchased from MedChemExpress. Usage Cited in: Mol Immunol. 2019 Mar:107:29-40. [Abstract]
Col1a1 and α-SMA protein levels are analyzed in cells treated with VP.
Verteporfin purchased from MedChemExpress. Usage Cited in: Mol Immunol. 2019 Mar:107:29-40. [Abstract]
Col1a1 and α-SMA protein levels are analyzed in cells treated with VP.
-
ACS Chem Biol
2025 Feb 21;20(2):464-478. PMID: 39818722 -
Dis Model Mech
Sex hormone receptors, calcium-binding protein and Yap1 signaling regulate sex-dependent liver cell proliferation following partial hepatectomy. [Abstract]2024 Oct 1;17(10):dmm050900. PMID: 39397390 -
Anim Cells Syst
Yap signalling regulates ductular reactions in mice with CRISPR/Cas9-induced glycogen storage disease type Ia. [Abstract]2022 Nov 7;26(6):300-309. PMID: 36605584 -
Arch Med Res
Infiltrating Macrophages Induced Stem-cell-like Features Through PI3K/AKT/GSK3β Signaling to Promote Neurofibroma Growth. [Abstract]2020 Feb;51(2):124-134. PMID: 32111496 -
-
Exp Cell Res
Mechanical stretch promotes the migration of mesenchymal stem cells via Piezo1/F-actin/YAP axis. [Abstract]2025 Feb 21;446(1):114461. PMID: 39988125 -
Exp Cell Res
Inhibition of RhoGEF/RhoA alleviates regorafenib resistance and cancer stemness via Hippo signaling pathway in hepatocellular carcinoma. [Abstract]2024 Mar 1;436(1):113956. PMID: 38341081 -
Arch Biochem Biophys
ApoM suppresses kidney renal clear cell carcinoma growth and metastasis via the Hippo-YAP signaling pathway. [Abstract]2023 Jul 15:743:109642. PMID: 37211224 -
Exp Cell Res
GDF15 induced by compressive force contributes to osteoclast differentiation in human periodontal ligament cells. [Abstract]2020 Feb 1;387(1):111745. PMID: 31765611 -
Mol Cell Endocrinol
FGF2 promotes the proliferation of injured granulosa cells in premature ovarian failure via Hippo-YAP signaling pathway. [Abstract]2024 Aug 1:589:112248. PMID: 38663484 -
J Pharm Biomed Anal
Analysis of verteporfin liposomal formulations for phospholipids and phospholipid degradation products by liquid chromatography-mass spectrometry (LC-MS). [Abstract]2022 Jan 20:208:114473. PMID: 34814079 -
Exp Dermatol
2022 Mar;31(3):320-329. PMID: 34623712 -
BMC Gastroenterol
Identification of the "Collagen-Macrophage" sub-category of patients with colorectal cancer as an extension of the CMS4 subtype with THBS2 as a therapeutic target. [Abstract]2025 May 8;25(1):342. PMID: 40340827 -
Mol Cell Probes
A dual-labeling molecule for efficient drug discovery of mitochondrial-lysosomal interactions. [Abstract]2024 Jul 5:76:101968. PMID: 38960210 -
Mol Biotechnol
Verteporfin Exerts Anticancer Effects and Reverses Resistance to Paclitaxel via Inducing Ferroptosis in Esophageal Squamous Cell Cancer Cells. [Abstract]2024 Sep;66(9):2558-2568. PMID: 37751128 -
Tissue Cell
2025 Aug 28:98:103111. PMID: 40902513 -
J Steroid Biochem Mol Biol
Vitamin D promotes wound healing in aged skin by modulating inflammation, angiogenesis, and EMT via the Hippo pathway. [Abstract]2025 Jun 2:252:106799. PMID: 40466431 -
Exp Eye Res
Verteporfin regulates corneal neovascularization through inhibition of YAP protein activation. [Abstract]2024 Jan:238:109747. PMID: 38072353 -
Oral Dis
Piezo1 mediates the degradation of cartilage extracellular matrix in malocclusion-induced TMJOA. [Abstract]2024 May;30(4):2425-2438. PMID: 37184045 -
Am J Cancer Res
PLCε knockdown prevents serine/glycine metabolism and proliferation of prostate cancer by suppressing YAP. [Abstract]2020 Jan 1;10(1):196-210. PMID: 32064161 -
J Cell Biochem
Vascular endothelial growth factor enhances tendon-bone healing by activating Yes-associated protein for angiogenesis induction and rotator cuff reconstruction in rats. [Abstract]2020 Mar;121(3):2343-2353. PMID: 31633245 -
Acta Histochem
YAP promotes wound healing in diabetic mice by improving endothelial cell function via the regulation of SEMA3B. [Abstract]2026 Apr 27;128(3):152335. PMID: 42048860 -
Theriogenology
LH promotes testosterone synthesis in rooster leydig cells through YAP1/ACSL4/SOAT1 pathway. [Abstract]2026 Apr 1:254:117813. PMID: 41529502 -
PLoS One
RETRACTED: SHP2 improved Late-onset fetal growth restriction via modulating ROS/BRD4/PI3K/YAP/PIGF signaling induced angiogenesis. [Abstract]2026 Feb 13;21(2):e0342649. PMID: 41686783 -
J Pharmacol Sci
YAP activation in Müller cells alleviates oxidative stress in the rat retina after intravitreal injection with methylglyoxal. [Abstract]2025 Apr;157(4):219-228. PMID: 40058941 -
PLoS One
TAOK1-mediated regulation of the YAP/TEAD pathway as a potential therapeutic target in heart failure. [Abstract]2024 Aug 9;19(8):e0308619. PMID: 39121041 -
Reprod Sci
The Inactivation of Hippo Signaling Pathway Promotes the Development of Adenomyosis by Regulating EMT, Proliferation, and Apoptosis of Cells. [Abstract]2023 Sep;30(9):2715-2727. PMID: 36940085
Verteporfin purchased from MedChemExpress. Usage Cited in: Reprod Sci. 2023 Sep;30(9):2715-2727. [Abstract]
Verteporfin (0-5 µM; 24 h) decreases the viability of Ishikawa cells in a concentration-dependent manner (IC50 = 1.345 µM).
Verteporfin purchased from MedChemExpress. Usage Cited in: Reprod Sci. 2023 Sep;30(9):2715-2727. [Abstract]
Verteporfin (0.5, 1, 2 µM) decreases the expression of anti-apoptotic marker B cell leukemia 2 (Bcl2), while increases the expression of pro-apoptotic protein Bcl2-associated X protein (Bax) in Ishikawa cells, in a concentration-dependent manner.
-
Cancer Manag Res
Downregulation of MicroRNA-130a Inhibits Oral Squamous Cell Carcinoma Proliferation and Metastasis via the Hippo-YAP Pathway. [Abstract]2021 Jun 17:13:4829-4840. PMID: 34168502 -
Biochem Biophys Res Commun
Resveratrol inhibits proliferation and induces apoptosis via the Hippo/YAP pathway in human colon cancer cells. [Abstract]2022 Dec 25;636(Pt 1):197-204. PMID: 36335870 -
Biochem Biophys Res Commun
RacGAP1 ameliorates acute kidney injury by promoting proliferation and suppressing apoptosis of renal tubular cells. [Abstract]2020 Jun 30;527(3):624-630. PMID: 32423815 -
Biochem Biophys Res Commun
Lovastatin attenuates angiotensin II induced cardiovascular fibrosis through the suppression of YAP/TAZ signaling. [Abstract]2019 May 14;512(4):736-741. PMID: 30926167 -
Biochem Biophys Res Commun
Low shear stress induces ERK nuclear localization and YAP activation to control the proliferation of breast cancer cells. [Abstract]2019 Mar 5;510(2):219-223. PMID: 30685085 -
J Oral Pathol Med
Role of the arecoline/YAP1/BMP4 pathway in promoting endothelial-mesenchymal transition in oral submucous fibrosis. [Abstract]2020 Apr;49(4):305-310. PMID: 31397922 -
Arch Oral Biol
Force-induced decline of TEA domain family member 1 contributes to osteoclastogenesis via regulation of Osteoprotegerin. [Abstract]2019 Apr:100:23-32. PMID: 30771694 -
Oncol Lett
Verteporfin suppresses osteosarcoma progression by targeting the Hippo signaling pathway. [Abstract]2021 Oct;22(4):724. PMID: 34429764 -
Eur J Oral Sci
Efficacy of metformin and verteporfin treatment alone or in combination in a murine head and neck cancer xenograft model. [Abstract]2025 Jan 8:e13034. PMID: 39780329 -
Curr Med Sci
2024 Aug;44(4):718-725. PMID: 38926331 -
Connect Tissue Res
IGF-1R/YAP signaling pathway is involved in collagen V-induced insulin biosynthesis and secretion in rat islet INS-1 cells. [Abstract]2022 Sep;63(5):498-513. PMID: 35129018 -
Stem Cells Dev
Hypoxia Protects Rat Bone Marrow Mesenchymal Stem Cells Against Compression-Induced Apoptosis in the Degenerative Disc Microenvironment Through Activation of the HIF-1α/YAP Signaling Pathway. [Abstract]2020 Oct 15;29(20):1309-1319. PMID: 32799744 -
Tohoku J Exp Med
Mammalian Sterile 20-Like Kinase 1 Knockdown Reduces Sevoflurane-Induced Oxidative Stress in HT22 and SH-SY5Y Cells via AKT Phosphorylation and YAP1 Transcriptional Activity. [Abstract]2026 Apr 23. PMID: 42021017 -
-
-
-
-
-
-
Heliyon
2024 Sep 2;10(17):e37265. PMID: 39296106 -
bioRxiv
Inhibition of RhoA-mediated secretory autophagy in megakaryocytes mitigates myelofibrosis in mice. [Abstract]2024 Dec 5:2024.12.04.626665. PMID: 39677616 -
-
Biomed Pharmacother
Self-delivery nanodrug to manipulate tumor microenvironment for boosting photodynamic cancer immunotherapy. [Abstract]2024 Jul 31:178:117220. PMID: 39094543 -
-
Biomed Pharmacother
2024 May 24:176:116768. PMID: 38795638 -
-
-
Heliyon
YAP promotes the healing of ischemic wounds by reducing ferroptosis in skin fibroblasts through inhibition of ferritinophagy. [Abstract]2024 Jan 16;10(2):e24602. PMID: 38298641 -
-
-
-
-
Biomed Pharmacother
YAP-regulated type II alveolar epithelial cell differentiation mediated by human umbilical cord-derived mesenchymal stem cells in acute respiratory distress syndrome. [Abstract]2023 Mar:159:114302. PMID: 36701989 -
-
-
-
-
-
Oxid Med Cell Longev
Irisin Ameliorates Intervertebral Disc Degeneration by Activating LATS/YAP/CTGF Signaling. [Abstract]2022 Jul 20:2022:9684062. PMID: 35915608 -
-
-
Elife
Selective YAP activation in Procr cells is essential for ovarian stem/progenitor expansion and epithelium repair. [Abstract]2022 Mar 14;11:e75449. PMID: 35285801 -
-
-
Biomed Pharmacother
2020 Jun;126:110080. PMID: 32203889 -
溶剤 & 溶解度
DMSO : 50 mg/mL (69.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
DMF : 10 mg/mL (13.91 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 1 mg/mL (1.39 mM); Suspended solution; Need ultrasonic
Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 10 mg/mL (13.91 mM); Suspended solution; Need ultrasonic
プロトコル
PDX cells co-cultured with S17 cells are treated with 16 combinations of verteporfin (60 nM, 120 nM, 180 nM, and 240 nM) and BMS-354825 (12 nM, 24 nM, 36 nM, and 48 nM). The viabilities of cells treated with each combination are measured after 48 h using FACS Aria flow cytometer. In order to estimate drug interaction between verteporfin and BMS-354825, a normalized isobologram and fraction affectedcombination index (CI) plot are made using CompuSyn software. CI values greater than 1.0 indicated antagonistic effects, equal to 1.0 additive effects, and below 1.0 synergistic effects.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice: PhLO cells (1.0×107/mouse) are injected intravenously into 6-week-old male NOG mice, which are then treated with vehicle, verteporfin (140 mg/kg/day), BMS-354825 (20 mg/kg/day), and a combination of these drugs from days 22 to 28. Verteporfin is administered by continuous subcutaneous infusion (c.s.c.) using Alzet osmotic pumps. An intraperitoneal injection (i.p.) is performed for BMS-354825. All mice are sacrificed on day 28 and the chimerism of leukemia cells is investigated by flow cytometer using an anti-human CD19 antibody and antimouse CD45 antibody. Blood concentrations of verteporfin are calculated by LCMS-2020.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
純度とドキュメンテーション
-
データシート (286 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Morishita T, et al. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with BMS-354825. Oncotarget. 2016 Aug 2. [Content Brief]
[2]. Pan W, et al. Verteporfin can Reverse the NSC 125973 Resistance Induced by YAP Over-Expression in HCT-8/T Cells without Photoactivation through Inhibiting YAP Expression. Cell Physiol Biochem. 2016;39(2):481-90. [Content Brief]
[3]. Donohue E, et al. The autophagy inhibitor verteporfin moderately enhances the antitumor activity of gemcitabine in a pancreatic ductal adenocarcinoma model.J Cancer. 2013 Aug 28;4(7):585-96. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMF / DMSO | 1 mM | 1.3912 mL | 6.9561 mL | 13.9123 mL | 34.7807 mL |
| 5 mM | 0.2782 mL | 1.3912 mL | 2.7825 mL | 6.9561 mL | |
| 10 mM | 0.1391 mL | 0.6956 mL | 1.3912 mL | 3.4781 mL | |
| DMSO | 15 mM | 0.0927 mL | 0.4637 mL | 0.9275 mL | 2.3187 mL |
| 20 mM | 0.0696 mL | 0.3478 mL | 0.6956 mL | 1.7390 mL | |
| 25 mM | 0.0556 mL | 0.2782 mL | 0.5565 mL | 1.3912 mL | |
| 30 mM | 0.0464 mL | 0.2319 mL | 0.4637 mL | 1.1594 mL | |
| 40 mM | 0.0348 mL | 0.1739 mL | 0.3478 mL | 0.8695 mL | |
| 50 mM | 0.0278 mL | 0.1391 mL | 0.2782 mL | 0.6956 mL | |
| 60 mM | 0.0232 mL | 0.1159 mL | 0.2319 mL | 0.5797 mL |